Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(5 sites)
Belgium
Institut Jules Bordet, Brussels Netherlands
Academisch Ziekenhuis Maastricht (Leading Centre), Maastricht, Limburg Spain
Institut Vall d'Hebron, Barcelona Age range
18 Years and older
Last updated October 2025